1Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis:contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol,1998, 31:224 -230.
2Schillinger M, Exner M, Mlekuseh W, et al. Restenosis after femoropopliteal PTA and elective stent implantation : predictive value of monocyte counts. J Endovasc Ther, 2003,10 (3) :557 - 565.
3Welt FG, Rogers C. Inflammation and restenosis in the stent era.Arterloscler Thromb Vase Biol,2002,22( 11 ) :1769 - 1776.
4Rogers C, Edelman ER, Simon DI. A mAb to the beta 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA, 1998, 95:10134 - 10139.
5Rogers C, Welt FGP, Karnovsky M J, et al. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol, 1996,16 : 1312 - 1318.
6Feldman L, Aguirre L, Ziol M, et al. Interleukin-10 inhibits neointimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation,2000,101 : 908-916.
7Tanguay JF, Hammoud T, Geoffroy P, et al. Chronic platelet and neutrophil adhesion: a causal role for neointimal hyperplasia in instent restenosis. J Endovasc Ther,2003,10(5 ) :968 - 977.
8Welt FGP, Edelman ER, Simon DI, et al. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol,2000,20:2553 -2558.
9Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation, 2002,105 : 2974 - 2980.
10Muller KM, Schmitz F. Morphological findings after stent implantation in the carotid artery. Pathologe, 2004,25 (2) :108 -115.
同被引文献21
1Badger S A, Soong C V, Lee B, et al. Prescribing practice of general practitioners in Northern Ireland for peripheral arterial disease[ J]. Angiology, 2008, 59 ( 1 ) : 57 - 63.
2Norgren L, Hiatt W R, Dommndy J A, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) [ J]. Eur J Vasc Endovasc Surg, 2007, 33 ( Suppl 1 ) : S1 - S75.
3Hirsch A T, Haskal Z J, Hertzer N R, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) [ J]. Circulation, 2006, 113 ( 11) : e463 - e654.
4Leung D A, Spinosa D J, Hagspiel K D, et al. Selection of stents for treating iliac arterial occlusive disease [ J ]. J Vasc Interv Radiol, 2003, 14(2 Pt 1) : 137 -152.
5Visser K, Hunink M G. Peripheral arterial disease: gadolinium-enhanced MR angiography versus color-guided duplex US:a meta-analysis [J]. Radiology, 2000, 216(1): 67-77.
6Hiatt W R, Money S R, Brass E P. Long-term safety of cilostazol in patients with peripheral artery disease : the CASTLE study ( Cilostazol : astudy in long-tern1 effects) [J]. J Vasc Surg, 2008, 47(2):330-3361.
7Grenacher L, Saam T, Geier A, et al. PTA versus Palmaz stent place- ment in femoropopliteal artery stenoses: results of a multicenter pro- spective randomized study (REFSA) [ J ]. Rofo, 2004, 176 (9) : 1302 - 1310.
8Muradin G S, Bosch J L, Stijnen T, et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis[J]. Radiology, 2001, 221 ( 1 ) : 137 - 145.
9Smith S C Jr, Milani R V, Arnett D K, et al. Atherosclerotic Vascular Disease Conference : Writing Group II : risk factors[J]. Circulation, 2004, 109(21): 2613-2616.
10Stone PA, Srivastiva M,Campbell J E, et al. Diagnosis and treatment of subclavian artery occlusive disease[J], Ex pert Rev Cardiovasc Ther,2010,8(9): 1275-1282.
